TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07231679: A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

Sponsor: Ingenia Therapeutics INC · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 94 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,382,780

Rescue Site Savings

+$903,040

Unlock Full NCT07231679 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07231679 Rescue Dossier →